It will drift lower until a strategy is communicated next Thursday to refocus the fundamental picture. Negative bias always carries the day in a situation like we're in. We all know the fundamentals going forward, let's see how the company plans to move forward from here. I have no doubts they will lay out a sensible plan for the rest of the year that will support the pps in due time. If the focus is on the pps and the day to day picture it's providing, then good luck with that. If you believe in the long term prospects, then the price really is not that important now. Yes it stinks to see this day after day, but the results of Eyeguard B were what they were and this is the fallout for however long it lasts. If you need to sell for whatever reason, that's the game we play and sometimes it kicks the short term trader in the rear. Everybody jumps on the bandwagon when things go south and try to look like geniuses. So we wait for direction from the company after the market closes on Thursday next week and go from there. What falls based on the perception of lost revenues (that's really what it comes down to) can recover based on therapies that put those revenues back in play. If they hit that objective(s), then it comes down to marking time. I believe we'll get there, it will just take longer than most had thought prior to last week's results from the Eyeguard B trial.
News 
Market Data 
Discover 
AI
